RxDoctor Payments Data

Thomas Treadwell, MD

Internal Medicine · Framingham, MANPI 1144260670

Payments from drug & device makers

$122,645in general payments, 2019–2025

Across 170 payments — averaging $721.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$71K
  • Janssen Products, LP$49K
  • Janssen Scientific Affairs, LLC$2K
  • Johnson & Johnson$311
  • E.r. Squibb & Sons, L.L.C.$125
  • Stryker$101
  • plus $43 from 2 others

What the payments were for

  • Consulting fees$4,7004%
  • Speaking & faculty fees$89,18585%
  • Travel & lodging$7,9118%
  • Food & beverage$3,3093%
  • Education$1100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$122,645 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$49,549
Medicare patients
215
Services billed
500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala186$812,283
OdefseyEmtricitab/Rilpiviri/Tenof Ala140$539,787
DescovyEmtricitabine/Tenofov Alafenam91$206,761
TivicayDolutegravir Sodium79$181,913
TriumeqAbacavir/Dolutegravir/Lamivudi25$136,755
GenvoyaElviteg/Cob/Emtri/Tenof Alafen21$115,672
JulucaDolutegravir/Rilpivirine29$105,374
EliquisApixaban124$39,365
PifeltroDoravirine11$20,628
SuboxoneBuprenorphine Hcl/Naloxone Hcl11$8,870
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl68$8,584
RetacritEpoetin Alfa-Epbx11$3,975
Omeprazole107$2,269
Atorvastatin Calcium112$2,149
Levothyroxine Sodium83$1,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$71,201$1,134,717298 claims
PfizerEliquis, Retacrit$16$43,340135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Framingham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →